Exchange Traded Concepts LLC Buys 222,869 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Exchange Traded Concepts LLC grew its stake in shares of OPKO Health, Inc. (NASDAQ:OPK) by 135.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 387,108 shares of the biotechnology company’s stock after buying an additional 222,869 shares during the period. Exchange Traded Concepts LLC owned 0.06% of OPKO Health worth $577,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC lifted its stake in shares of OPKO Health by 1,086.9% during the 3rd quarter. SG Americas Securities LLC now owns 135,856 shares of the biotechnology company’s stock valued at $202,000 after buying an additional 124,410 shares in the last quarter. Algert Global LLC bought a new stake in OPKO Health during the second quarter valued at about $44,000. Squarepoint Ops LLC bought a new stake in OPKO Health during the second quarter valued at about $592,000. Rubric Capital Management LP raised its holdings in OPKO Health by 800.0% during the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock valued at $55,528,000 after acquiring an additional 39,486,490 shares during the period. Finally, Hollencrest Capital Management raised its holdings in OPKO Health by 14.0% during the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 11,020 shares during the period. 64.63% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other OPKO Health news, major shareholder Opko Health, Inc. sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $34.49, for a total transaction of $1,724,500.00. Following the completion of the transaction, the insider now owns 2,646,972 shares in the company, valued at $91,294,064.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 586,444 shares of company stock worth $19,494,627. Corporate insiders own 47.26% of the company’s stock.

OPKO Health Trading Up 0.7 %

Shares of OPK stock opened at $1.47 on Friday. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.75. The company has a current ratio of 1.63, a quick ratio of 1.36 and a debt-to-equity ratio of 0.13. The stock’s 50-day moving average price is $1.55 and its 200-day moving average price is $1.40. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.20 and a beta of 1.63.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.08. The firm had revenue of $182.20 million for the quarter, compared to analysts’ expectations of $184.70 million. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The business’s revenue was down 31.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) earnings per share. Equities research analysts predict that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on OPK. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th. StockNews.com raised OPKO Health to a “sell” rating in a report on Saturday, July 27th. Piper Sandler reissued an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a report on Friday, September 20th.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.